|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM014670720 |
| 003 |
DE-627 |
| 005 |
20231221061556.0 |
| 007 |
tu |
| 008 |
231221s1992 xx ||||| 00| ||jpn c |
| 028 |
5 |
2 |
|a pubmed24n0049.xml
|
| 035 |
|
|
|a (DE-627)NLM014670720
|
| 035 |
|
|
|a (NLM)1485588
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a jpn
|
| 100 |
1 |
|
|a Kakehi, Y
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Circumvention of the intrinsic multidrug-resistance in renal cell carcinoma
|
| 264 |
|
1 |
|c 1992
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 12.02.1993
|
| 500 |
|
|
|a Date Revised 21.11.2013
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Most of renal cell carcinomas (RCCs) are refractory at the start of chemotherapy. We have demonstrated that the frequently elevated expression of the multidrug resistance gene (MDR) in RCCs is associated with the intrinsic vinca alkaloids and anthracyclines resistance. The preliminary clinical trials using verapamil or amiodarone in combination with vinblastine or doxorubicin to overcome multidrug-resistant (MDR) tumors could not achieve satisfactory results owing to severe cardiovascular toxicities of such reversing agents. In the present study, we studied the sensitizing ability of bis-benzyl-isoquinoline (cepharanthine) and SDB-ethylenediamine (N-1379) in natural MDR kidney cancer cells. Cepharanthine remarkably sensitized vinblastine and doxorubicin sensitivities in those cells with high MDR RNA levels. From a clinical point of view, cepharanthine seems to be a potent and less toxic agent to treat natural MDR kidney cancers
|
| 650 |
|
4 |
|a Case Reports
|
| 650 |
|
4 |
|a English Abstract
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
7 |
|a Alkaloids
|2 NLM
|
| 650 |
|
7 |
|a Benzylisoquinolines
|2 NLM
|
| 650 |
|
7 |
|a Ethylenediamines
|2 NLM
|
| 650 |
|
7 |
|a Terpenes
|2 NLM
|
| 650 |
|
7 |
|a N-solanesyl-N,N'-bis(3,4-dimethoxybenzyl)ethylenediamine
|2 NLM
|
| 650 |
|
7 |
|a 103190-36-9
|2 NLM
|
| 650 |
|
7 |
|a Vinblastine
|2 NLM
|
| 650 |
|
7 |
|a 5V9KLZ54CY
|2 NLM
|
| 650 |
|
7 |
|a cepharanthine
|2 NLM
|
| 650 |
|
7 |
|a 7592YJ0J6T
|2 NLM
|
| 650 |
|
7 |
|a Doxorubicin
|2 NLM
|
| 650 |
|
7 |
|a 80168379AG
|2 NLM
|
| 700 |
1 |
|
|a Segawa, T
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hashimura, T
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yoshida, O
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Hinyokika kiyo. Acta urologica Japonica
|d 1962
|g 38(1992), 11 vom: 10. Nov., Seite 1319-24
|w (DE-627)NLM012631779
|x 0018-1994
|7 nnns
|
| 773 |
1 |
8 |
|g volume:38
|g year:1992
|g number:11
|g day:10
|g month:11
|g pages:1319-24
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_20
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_60
|
| 912 |
|
|
|a GBV_ILN_72
|
| 912 |
|
|
|a GBV_ILN_120
|
| 912 |
|
|
|a GBV_ILN_350
|
| 912 |
|
|
|a GBV_ILN_2001
|
| 912 |
|
|
|a GBV_ILN_2003
|
| 912 |
|
|
|a GBV_ILN_2005
|
| 912 |
|
|
|a GBV_ILN_2006
|
| 912 |
|
|
|a GBV_ILN_2008
|
| 912 |
|
|
|a GBV_ILN_2010
|
| 912 |
|
|
|a GBV_ILN_2012
|
| 912 |
|
|
|a GBV_ILN_2018
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 38
|j 1992
|e 11
|b 10
|c 11
|h 1319-24
|